Table A9:
Intervention: CGM + MDI vs. SMBG + | ||||
---|---|---|---|---|
MDI | GOLDa | DIAMONDb | ||
Steps | ||||
1. Calculate % change relative to baseline | 5.15 | 10.47 | ||
2. Obtain RR of complications from DCCT | Retinopathy: 0.462 | Nephropathy: 0.611 | Neuropathy: 0.390 | CVD: 0.643 |
3. Calculate RRR from retinopathy (DCCT): RRR = 1 - RR | 0.538 | 0.389 | 0.610 | 0.357 |
4. Calculate RRR change owing to 1% reduction in A1C level (15.9% A1C reduction from DCCT) | 0.034 | 0.024 | 0.038 | 0.022 |
GOLD | ||||
5. Calculate RRR for intervention | 0.174 | 0.126 | 0.197 | 0.116 |
6. Calculate RR: RR = 1 - RRR | 0.826 | 0.874 | 0.803 | 0.884 |
DIAMOND | ||||
5. Calculate RRR for intervention | 0.354 | 0.256 | 0.401 | 0.235 |
6. Calculate RR: RR = 1 - RRR | 0.646 | 0.744 | 0.599 | 0.765 |
Average RR (GOLD and DIAMOND) | 0.736 | 0.809 | 0.701 | 0.825 |
Abbreviations: A1C, glycated hemoglobin; CGM, continuous glucose monitoring; CVD, cardiovascular disease; DCCT, Diabetes Control and Complications Trial; MDI, multiple daily injections; SMBG, self-monitoring of blood glucose; RR, relative risk; RRR relative risk reduction.
The GOLD study31 was a randomized controlled trial conducted in Sweden with a 26-week duration. The mean age of study participants was 44 years, and the mean duration of diabetes duration was 22 years.
The DIAMOND study24 was randomized controlled trial conducted in the United States with a 24-week duration. The mean age of study participants was 48 years, and the mean duration of diabetes was 19 years.